CSL vs PME – Which is the better investment?

Aussie investors are blessed with a wealth of high quality stocks operating in a variety of healthcare sectors. Healthcare globally has significant tailwinds impacting share prices.

First and foremost is demographics. In many countries around the world, aging populations will require more chronic disease management and long term care.

Second is growth in chronic diseases like diabetes, heart disease, and a variety of cancers.

Third, Artificial Intelligence (AI) has entered the sector, accelerating technologies for improving operational and administrative efficiency and drug discovery and other forms of treatment.

CSL and PME (Pro Medicus) operate in different healthcare subsectors. CSL is a pharmaceutical and biotechnology company, while Pro Medicus is a medical technology company. CSL is a global healthcare heavyweight with plasma therapies, vaccines and kidney care exposure. PME is a much smaller, higher-margin imaging software business whose growth is being driven by contract wins and rollout in the US hospital market. That makes this less of a “which company is the better investment?” question and more of a “which type of healthcare exposure do you want?”

CSL now has three operating divisions; CSL Behring ,CSL Seqirus, and CSL Vifor. CSL Behring provides blood plasma treatments to treat a variety of conditions, from bleeding disorders and neurological conditions to deficiencies in the immune system. CSL Seqirus is a global leader in influenza vaccine protection. CSL Vifor is a relatively recent addition to the CSL family, acquired in 2023. Vifor provides treatments for kidney-related issues (nephrology) and iron deficiencies.

Pro Medicus is classified in the Health IT & Radiology business sector. The company operates globally with an intense focus on the massive US market. The company’s flagship product is the renowned Visage 7 Enterprise Imaging Software platform  for hospitals and large radiology groups. The company’s business model is Software as a Service (SaaS), a highly effective model for generating recurring revenues. Pro Medicus customers typically sign long-term contracts.

Modern healthcare systems rely on massive amounts of medical images, from X-rays to MRIs (magnetic resonance imaging) and CT scans (computed tomography.) Pro Medicus software allows efficient storage and retrieval of this data.

What Are CSL and Pro Medicus Shares Worth?

In reality, the “worth” of an individual stock is in the eyes of the investor. There are investors who believe a company’s worth is embedded in its intrinsic value, regardless of its share price. Determining a stock’s intrinsic value begins with an assessment of the underlying fundamentals of the company’s underlying business characteristics, ignoring conventional market sentiment and speculation regarding what the stock is worth. The approach of assessing the underlying characteristics is called fundamental analysis.

In contrast, there are investors who believe a stock is worth whatever market participants are willing to pay. In their eyes, price history and movement outweigh fundamental characteristics.

Calculating support and resistance levels for a stock is a favored method for determining when to buy and sell a stock based on its “worth”, or price movement. The support level acts as a floor for the stock – a price below which the stock does not fall over a time period. Resistance is the ceiling – a price above which the stock will not rise.

There are several methods of calculating support and resistance, none of them are exactly for the beginner, but they can be learnt.

CSL closed out March below $140, down 45% in 12 months, breaking through any meaningful support before 2018. In the absence of a quick recovery, the share price may continue to decline. Investors who favoured the technical analysis of price movements are likely to see the break as a SELL signal. Investors favouring the fundamental approach will typically reassess the break in support to determine if the stock’s fundamentals have changed or if the fall can be attributed to market sentiment.

Support levels for Pro Medicus as of late March appear to be $120, although in recent days the shares have broken below. The shares have charted a similar path over the past year, also sharply lower, down 40%. It’s been a tough time to be in either name, although over the past 5 years, the trajectory is quite different, with PME continuing to put up strong gains on the period, whilst CSL is down by a similar amount to the 1 year.

Price ratios are the favoured method for investors assessing a company’s fundamentals. These ratios gauge a company’s share price against different metrics, like earnings, book value, and cash flow.

Higher valuation ratios suggest investors are willing to pay more for a stock than current fundamentals warrant in expectation of superior future growth. Pro Medicus clearly falls in the category of growth stocks, with a P/E of 55, whilst CSL trades more modestly at 15.8x. That is not a small gap in valuation, but a completely different market expectation. CSL’s multiple says “prove the recovery.” PME’s multiple says “keep delivering near-perfect execution.”

That makes CSL the easier stock to justify if you are at all valuation-sensitive, while PME makes more sense for those who care more about quality of growth than entry multiple.

Do CSL and PME Pay Dividends?

Yes. For investors looking for interest income from their stock holdings, dividend payments is a consideration in determining the worth of the company. Many high growth stocks like PME do not pay dividends, preferring to invest a maximum amount in growing the company.

In that regard, PME is the exception, having increased its dividend payments in each year over the last decade, although its dividend yield is low, with a five year average yield of 0.27%. The most recent dividend payment was for $0.55 per share.

CSL suspended its dividend in FY 2024, resuming payments in FY2025 with a dividend payment of $4.52. The five year average dividend yield is low, at 1.19%.

CSL vs PME: Which is the Better Investment?

Conventional wisdom suggests the answer to the question of which is the better investment depends on an individual investor’s goals, risk tolerance, and the desired length of time for holding the stock. CSL is universally applauded as a stable blue chip stock with consistent dividends and a defensive character. While Pro Medicus trails CSL in dividend payments, it has a higher yield and as a major healthcare player should also be considered defensive in character.

There are two reasons that seem to clearly point to Pro Medicus as the better investment. The first is the addressable market for the products each of these companies deliver. CSL is limited to specific medical conditions, while PME’s software spans the entire spectrum of healthcare products and services.

The second is price appreciation. CSL has yet to fully recover from the impact of COVID curtailing the use of its treatments. However, Pro Medicus has been crushing CSL for the five years.

Over five years PME is up 174% while CSL has dropped 32%, and year over year PME is up 73.3% while CSL has fallen 47%.

The reason investors still care about CSL is franchise quality. Even after the weak half, CSL maintained FY2026 guidance and increased its share buyback program from US$500 million to US$750 million. That is a sign management still sees long-term value despite the near-term earnings reset.

The risk is obvious: this is no longer a stock you buy purely for smooth, dependable execution. The half-year numbers showed the extent of the near-term disruption, and the market has already punished the shares for that. So the CSL case today is less about momentum and more about whether you believe the underlying global plasma and specialty healthcare franchise will reassert itself over time.

PME is the opposite: much smaller, much more concentrated, but currently far stronger on growth and margin momentum. Pro Medicus’ February 2026 interim result showed revenue up 28.4%, underlying profit before tax up 29.7%, and reported NPAT up 230.9%, while remaining debt-free and highly cash-generative. That is why the market still treats PME more like a premium growth stock than a standard healthcare company

One area where CSL wins out is if income is a priority, with CSL’s dividend yield of 2.07% dwarfing that of PME (0.53%).

CSL also maintained its interim dividend at US$1.30 per share in the February 2026 half-year result and expanded its buyback. PME declared a fully franked interim dividend of 32 cents per share in its FY2026 interim result, but the investment case is clearly not built around income.

In Summary – The Short Look

If you are still looking to split hairs between the two, and want the short case for each, this is for you.

CSL gives you a larger moat, broader therapeutic exposure, more geographic diversification, and less dependence on a single product category or contract pipeline. If the current operational reset passes and execution improves, the stock has room to re-rate from a much lower starting multiple than markets were once used to paying.

PME gives you faster structural growth, a capital-light software-style model, elite margins, and continuing exposure to digitisation inside diagnostic imaging. If contract wins continue and implementations scale smoothly, PME can keep growing much faster than a mature global healthcare company like CSL.

So, in summary, for most valuation-conscious investors, CSL is the easier stock to justify today, with growth from here dependant upon a recovery rather than a miracle. PME is still a terrific business, and would be one for those who are willing to pay up for superior growth, and margins, with a narrower margin for error operationally. CSL wins on resilience and valuation, whilst PME wins on momentum.